Summary
Highlights
Weight loss injections, specifically GLP-1s like Ozempic, Mounjaro, and Saxenda, have become increasingly popular, with an estimated 1.5 million people in the UK using them by 2025. This surge in use is attributed to rising obesity rates in the UK (28% obese, 36% overweight) and the desire to address health impacts and societal pressures linked to body image.
Individuals share their experiences with weight loss injections, highlighting years of struggle with diet and weight regain. GLP-1 medications work by mimicking a natural hormone that regulates blood sugar and appetite, slowing digestion and increasing feelings of fullness, thus leading to reduced calorie intake and weight loss.
While effective, these drugs come with a significant financial cost for private users, with some resorting to selling personal items to maintain payments. Deciding to stop the injections is a personal choice, but stopping abruptly can lead to unpleasant side effects and the rapid return of appetite, often described as an 'avalanche' or 'tsunami' of food noise.
'Food noise' refers to persistent, repetitive thoughts about food, a phenomenon many users experience after discontinuing GLP-1s. The medication effectively silences this, providing a sense of control for emotional eaters. The return of food noise can be traumatic, leading to fears of weight regain and a struggle to maintain lifestyle changes.
Weight regain is common after stopping GLP-1s, with 60-80% of lost weight potentially returning within one to three years. This is due to the body's natural tendency to regain lost weight (set point theory) and a potential dip in the body's natural GLP-1 production. Maintaining lifestyle changes initiated during medication use is crucial to prevent this.
Many users express a desire to stay on GLP-1s long-term due to the sense of control and the fear of returning to previous weight. However, the long-term effects of these relatively new medications are still largely unknown, including potential issues with the pancreas, kidneys, and gallbladder. The popularity of these jabs is also shifting societal perceptions of thinness and obesity, raising concerns about over-reliance on pharmaceuticals rather than broader lifestyle and governmental changes.